4BIO CAPITAL is a trade name of 4BIO Ventures Management Ltd, which is authorised and regulated by the Financial Conduct Authority, register number 775193
© 2015-2019 by 4BIO Ventures Management Ltd

GSK Hands Off Rare Disease Gene Therapy Portfolio to Orchard Therapeutics

April 13, 2018

GlaxoSmithKline (GSK) said today it will hand off its rare disease gene therapy portfolio — including its European-approved gene therapy Strimvelis™ — to two-year-old startup Orchard Therapeutics in return for taking a 19.9% stake in the acquirer, as well as undisclosed milestone payments and royalties, and a seat on Orchard’s board. Orchard Therapeutics is a portfolio company of 4BIO Capital.

 

Read more at GEN.

Please reload

ARCHIVE
Please reload

SEARCH BY TAGS
Please reload

FOLLOW US